Alpha 2.0
Login Register
» Authors » Teresa Gamucci

Teresa Gamucci

Explore the profile of Teresa Gamucci including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 100
Citations 1522
Followers 0
Related Specialties
Oncology
General Medicine
Science
Top 10 Co-Authors
Patrizia Vici
Laura Pizzuti
Isabella Sperduti
Clara Natoli
Maddalena Barba
Luca Moscetti
Paolo Marchetti
Lucia Mentuccia
Antonino Grassadonia
Marcello Maugeri-Sacca
Published In
Oncotarget
PLoS One
J Cancer
Cancers (Basel)
J Cell Physiol
Affiliations
Soon will be listed here.
Recent Articles
1.
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study
Krasniqi E, Filomeno L, Arcuri T, Di Lisa F, Astone A, Cutigni C, et al.
Cancers (Basel) . 2024 Dec; 16(23). PMID: 39682290
Background/objectives: HER2-positive breast cancer (HER2BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been...
2.
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
Cazzaniga M, Pronzato P, Amoroso D, Bernardo A, Biganzoli L, Bisagni G, et al.
Cancers (Basel) . 2024 Jan; 16(1). PMID: 38201545
GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes-based regimens, or taxanes + targeted agents, mainly...
3.
Prognostic value of gender and primary tumor location in metastatic colon cancer
Grassadonia A, Carletti E, De Luca A, Vici P, Di Lisa F, Filomeno L, et al.
J Cancer . 2023 Oct; 14(15):2751-2758. PMID: 37781086
Sex might influence prognosis in patients affected by colorectal cancer. We retrospectively studied a cohort of patients affected by metastatic colon cancer (mCC) stratified by sex and primary tumor location....
4.
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
Fabbri A, Nelli F, Botticelli A, Giannarelli D, Marrucci E, Fiore C, et al.
Front Oncol . 2023 Jul; 13:1177681. PMID: 37441419
Purpose: Clinical trials have shown a significant increase in pathologic complete response (pCR) with the addition of pertuzumab to neoadjuvant chemotherapy for patients with early-stage HER-2 positive breast cancer. To...
5.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from , a multicentric, observational study
Di Lisa F, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, et al.
Front Oncol . 2023 Jun; 13:1152123. PMID: 37260975
Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine,...
6.
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
Krasniqi E, Di Lisa F, Di Benedetto A, Barba M, Pizzuti L, Filomeno L, et al.
Cancers (Basel) . 2022 Oct; 14(19). PMID: 36230758
The Hippo pathway and its two key effectors, Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), are consistently altered in breast cancer. Pivotal regulators of cell metabolism such...
7.
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Pizzuti L, Krasniqi E, Sperduti I, Barba M, Gamucci T, Mauri M, et al.
Ther Adv Med Oncol . 2022 Feb; 13:17588359211059873. PMID: 35173816
Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is...
8.
Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series
Ippolito E, Silipigni S, Matteucci P, Greco C, Pantano F, DAuria G, et al.
Cancers (Basel) . 2022 Jan; 14(2). PMID: 35053467
(1) Background: This study aims to assess the safety and efficacy of fractionated SRT (fSRT) and pertuzumab-trastuzumab (PT) in patients with breast cancer brain metastases (BCBM). (2) Methods: Patients with...
9.
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Sacca M, Gamucci T, et al.
Sci Rep . 2021 Jul; 11(1):13770. PMID: 34215766
In metastatic breast cancer (mBC), the change of human epidermal growth factor receptor 2 (HER2) status between primary and metastatic lesions is widely recognized, however clinical implications are unknown. Our...
10.
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
Puglisi F, Gerratana L, Lambertini M, Ceppi M, Boni L, Montemurro F, et al.
NPJ Breast Cancer . 2021 Jun; 7(1):82. PMID: 34183674
The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated...